Yuki Date

Yuki Date

Auto-generated profile, based on publicly available information

Yuki Date

Department of Molecular Bone Biology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020
Verified
Journal Article
Open access
YDYuki Date
Yuki Date
KIKosei Ito
Kosei Ito
The RUNX transcription factors serve as master regulators of development and are frequently dysregulated in human cancers. Among the three family members, RUNX3 is the least studied, and has long been considered to be a tumor-suppressor gene in human cancers. This idea is mainly based on the observation that RUNX3 is inactivated by genetic/epigenetic alterations or protein mislocalization during the initiation of tumorigenesis. Recently, this paradigm has been challenged, as several lines of evidence have shown that RUNX3 is upregulated over the course of tumor development. Resolving this paradox and understanding how a single gene can exhibit both oncogenic and tumor-suppressive properties is essential for successful drug targeting of RUNX. We propose a simple explanation for the duality of RUNX3: p53 status. In this model, p53 deficiency causes RUNX3 to become an oncogene, resulting in aberrant upregulation of MYC.

22 November 2021 in Oncogene
Verified
Journal Article
Closed access
PDF file
SOShohei Otani
Shohei Otani
YDYuki Date
Yuki Date
TUTomoya Ueno
Tomoya Ueno
TITomoko Ito
Tomoko Ito
SKShuhei Kajikawa
Shuhei Kajikawa
KIKosei Ito
Kosei Ito

4 July 2023 in Oncogene
Verified
Journal Article
Closed access
PDF file
KOKeisuke Omori
Keisuke Omori
SOShohei Otani
Shohei Otani
YDYuki Date
Yuki Date
TUTomoya Ueno
Tomoya Ueno
TITomoko Ito
Tomoko Ito
KIKosei Ito
Kosei Ito

26 June 2024 in Cancer Science
Verified
Journal Article
Open access
TUTomoya Ueno
Tomoya Ueno
SOShohei Otani
Shohei Otani
YDYuki Date
Yuki Date
YKYu Katsuma
Yu Katsuma
YNYuma Nagayoshi
Yuma Nagayoshi
KIKosei Ito
Kosei Ito
Osteosarcoma (OS) in humans is characterized by alterations in the TP53 gene. In mice, loss of p53 triggers OS development, for which c‐Myc (Myc) oncogenicity is indispensable. However, little is known about which genes are targeted by Myc to promote tumorigenesis. Here, we examined the role of γ‐glutamylcyclotransferase (Ggct) which is a component enzyme of the γ‐glutamyl cycle essential for glutathione homeostasis, in human and mouse OS development. We found that GGCT is a poor prognostic factor for human OS, and that deletion of Ggct suppresses p53‐deficient osteosarcomagenesis in mice. Myc upregulates Ggct directly by binding to the Ggct promoter, and deletion of a Myc binding site therein by genome editing attenuated the tumorigenic potential of p53‐deficient OS cells. Taken together, these results show a rationale that GGCT is widely upregulated in cancer cells and solidify its suitability as a target for anticancer drugs.

8 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
YDYuki Date
Yuki Date
YSYukiko Sasazawa
Yukiko Sasazawa
MKMitsuhiro Kitagawa
Mitsuhiro Kitagawa
KGKentaro Gejima
Kentaro Gejima
ASAyami Suzuki
Ayami Suzuki
SSShinji Saiki
Shinji Saiki
Autophagy-lysosome pathway plays an indispensable role in the intracellular protein quality control system, degrading abnormal organelles and proteins. Among these proteins is α-Synuclein (αSyn), which is associated with the pathogenesis of Parkinson’s disease (PD). However, the activation of this lysosome-dependent degradation strategy is restricted by enzyme complementation. In this study, we focused on the phase of autophagosome-lysosome fusion around the microtubule organizing center (MTOC) that leads to αSyn degradation. Through high-throughput chemical screening, we identified six clinically available drugs that enhance autophagy and can accumulate lysosomes around the MTOC from approximately 1,200 drugs screened. We further demonstrated that these compounds induce lysosomal clustering through a JIP4-TRPML1-dependent mechanism, which is associated with autophagy induction. Among these, the lysosomal clustering compound albendazole was observed to promote the autophagy-dependent degradation of Triton-X-insoluble proteasome inhibitor-induced aggregates (p62). In a cellular PD model, albendazole boosted the degradation of insoluble αSyn, an effect that was reversed upon the addition of bafilomycin A1. Our results suggest that lysosomal clustering can facilitate the breakdown of protein aggregates. Therefore, compounds that promote lysosomal clustering may offer a promising therapeutic strategy against neurodegenerative diseases characterized by the presence of aggregate-prone proteins.